Lilly Pulls the Plug on Mix-and-Inject Glugagon Rescue Kits

For those who didn ' t hear the news when it broke, diaTribe news reported (seehttps://diatribe.org/glucagon-options-expand-lilly-discontinues-emergency-kit for the news) that Lilly announced that the company intends to discontinue manufacturing its traditional Glucagon Emergency Kitshttps://www.lillyglucagon.com/ by the end of 2022. The kits are old-school, mix& inject kits that many patients (and caregivers alike) really despise because they are rather cumbersome and inconvenient to use when time is of the essence. Having an unpopular product works in the absence of competition, but when newer, more convenient products or cheaper generic products emerge, the product has reached the end of its product lifecycle.Previously, on July 24, 2019, Lilly announced (seehttps://www.prnewswire.com/news-releases/baqsimi-glucagon-nasal-powder-3-mg-the-first-and-only-nasally-administered-glucagon-to-treat-severe-hypoglycemia-in-adults-and-children-with-diabetes-ages-four-years-and-older-approved-by-fda-300890782.html for details) that it had received FDA approval for BAQSIMI (see the FDA approval letter athttps://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/210134Orig1s000ltr.pdf for details) which aimed to be a more convenient and easier-to-use glucagon product. Some patients don ' t like the nasally administered product and therefore prefer easier-to-use " pens " which are similar to EpiPens. Fortunately, those options now exist too.Cause #1: Newer, More Convenient Glucagon...
Source: Scott's Web Log - Category: Endocrinology Tags: Eli Lilly and Company glucagon PBM rebates Source Type: blogs